D. Grimwade

D. Grimwade, M. Joannides, 2010, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

positive chronic eosinophilic leukemia - FIP1L1-PDGFRA responses and achievement of complete molecular remission in Low-dose imatinib mesylate leads to rapid induction of major molecular

M. Rondoni, G. Martinelli, C. Preudhomme, 2013 .

REFINEMENT OF CYTOGENETIC CLASSIFICATION IN AML: DETERMINATION OF PROGNOSTIC SIGNIFICANCE OF RARE RECURRING CHROMOSOMAL ABNORMALITIES AMONGST 5635 YOUNGER ADULTS TREATED IN THE UK MRC TRIALS

R. Hills, D. Grimwade, C. Harrison, 2009 .

Analysis of t(15;17) chromosomal breakpoint sequences in therapy‐related versus de novo acute promyelocytic leukemia: Association of DNA breaks with specific DNA motifs at PML and RARA loci

R. Schlenk, H. Döhner, F. Lo‐Coco, 2010, Genes, chromosomes & cancer.

Genomic anatomy of the specific reciprocal translocation t(15;17) in acute promyelocytic leukemia

M. Segal, A. Reiter, N. Cross, 2003, Genes, chromosomes & cancer.

MYELOID NEOPLASIA Loss of imprinting at the 14q32 domain is associated with microRNA overexpression in acute promyelocytic leukemia

J. Gribben, D. Grimwade, B. Young, 2014 .

The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties.

K Wheatley, D. Grimwade, C. Harrison, 1998, Blood.

The changing paradigm of prognostic factors in acute myeloid leukaemia.

D. Grimwade, 2012, Best practice & research. Clinical haematology.

Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12.

E. van den Berg, R. Hills, D. Grimwade, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia.

R. Hills, A. Pizzey, K. Mills, 2005, Blood.

Screening for core binding factor gene rearrangements in acute myeloid leukemia

D. Grimwade, 2002, Leukemia.

Molecular characterisation of patients with APL entered into the UK MRC ATRA trial: Relationship of PML breakpoint with additional cytogenetic abnormalities and outcome [Abstract]

S. Langabeer, D. Grimwade, P. Gorman, 1997 .

Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer Program

H. Cavé, J. Dongen, J. Aerts, 2003, Leukemia.

Molecular MRD status and outcome after transplantation in NPM1 mutated AML: results from the UK NCRI AML17 study.

N. Potter, C. Craddock, R. Hills, 2019, Blood.

Comparative genomic analysis of PML and RARA breakpoints in paired diagnosis/relapse samples of patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy

M. Voso, F. Lo‐Coco, G. Basso, 2018, Leukemia & lymphoma.

The experience of the International Consortium on Acute Promyelocytic Leukemia in monitoring minimal residual disease in acute promyelocytic leukaemia

F. Lo‐Coco, M. Sanz, D. Grimwade, 2018, British journal of haematology.

De ﬁ ning minimal residual disease in acute myeloid leukemia: which platforms are ready for “ prime time ” ?

D. Grimwade, S. Freeman, 2014 .

RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias Strikingly different molecular relapse kinetics in NPM1c, PML-RARA,

D. Grimwade, H. Hasle, P. Hokland, 2013 .

Development of standardized approaches to reporting of minimal residual disease data using a reporting software package designed within the European LeukemiaNet

S. Schnittger, D. Grimwade, K. Tobal, 2011, Leukemia.

The Management of Acute Promyelocytic Leukemia Presenting During Pregnancy

D. Grimwade, J. Jovanovic, D. Culligan, 2007 .

Minimal residual disease directed therapy for childhood acute myeloid leukaemia: the time is now

D. Grimwade, P. Virgo, N. Goulden, 2006, British journal of haematology.

CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Presenting White Blood Cell Count and Kinetics of Molecular Remission Predict Prognosis in Acute Promyelocytic Leukemia Treated With All- Trans Retinoic Acid: Result of the Randomized MRC Trial

D. Grimwade, E. Solomon, A. Goldstone, 2022 .

Structure, organization, and dynamics of promyelocytic leukemia protein nuclear bodies.

K. Howe, P. Freemont, D. Grimwade, 1998, American journal of human genetics.

Variability in the levels of PML-RAR alpha fusion transcripts detected by the laboratories participating in an external quality control program using several reverse transcription polymerase chain reaction protocols.

I. Marugán, D. Colomer, F. Lo Coco, 2001, Haematologica.

Retinoic Acid: Result of the Randomized MRC Trial All-Trans Predict Prognosis in Acute Promyelocytic Leukemia Treated With Presenting White Blood Cell Count and Kinetics of Molecular Remission

D. Grimwade, E. Solomon, A. Goldstone, 2013 .

D. Grimwade, E. Solomon, A. Goldstone, 2022 .

RT-PCR in diagnosis and disease monitoring of acute promyelocytic leukemia (APL).

S. Langabeer, D. Grimwade, E. Solomon, 1998, Methods in molecular biology.

Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the Randomized MRC Trial.

D. Grimwade, E. Solomon, A. Goldstone, 1999, Blood.

Identification of PML/RARα rearrangements in suspected acute promyelocytic leukemia using fluorescence in situ hybridization of bone marrow smears: a comparison with cytogenetics and RT-PCR in MRC ATRA trial patients

A. Chase, D. Grimwade, A. Goldstone, 2000, Leukemia.

Acute promyelocytic leukaemia with t(11;17)(q23;q12‐21) and a good initial response to prolonged ATRA and combination chemotherapy

D. Grimwade, D. Culligan, Y. Chee, 1998, British journal of haematology.

The importance of diagnostic cytogenetics in older patients with AML: Analysis of 922 patients entered into the MRC AML 11 trial.

D. Grimwade, A. Goldstone, A. Burnett, 1999 .

com-Allogeneic hematopoietic cell transplantation improves outcome of adults with t(6;9) acute myeloid leukemia: results from an international collaborative study

E. Estey, R. Schlenk, R. Hills, 2019 .

Prognostic value of monitoring a candidate immunophenotypic leukemic stem/progenitor cell population in patients allografted for acute myeloid leukemia

P. Vyas, C. Bradbury, C. Craddock, 2014, Leukemia.

What happens subsequently in AML when cytogenetic abnormalities persist at bone marrow harvest? Results of the 10th UK MRC AML Trial

D. Grimwade, A. Burnett, K. Wheatley, 1997, Bone Marrow Transplantation.

DNA methylation-independent loss of RARA gene expression in acute myeloid leukemia.

M. Boix-Chornet, T. Enver, A. Zelent, 2008, Blood.

Evidence for direct involvement of epirubicin in the formation of chromosomal translocations in t(15;17) therapy-related acute promyelocytic leukemia.

N. Osheroff, F. Lo‐Coco, C. Felix, 2010, Blood.

Quantitation of Leukemic Stem Cell Populations Predicts Clinical Outcome in Acute Myeloid Leukaemia

I. Weissman, P. Vyas, C. Craddock, 2011 .

Salvage of patients with acute promyelocytic leukaemia with residual disease following ABMT performed in second CR using all‐trans retinoic acid

R. Jamal, P. Veys, D. Grimwade, 1998, British journal of haematology.

Central nervous system relapse in acute promyelocytic leukaemia in patients treated with all‐trans retinoic acid

Simpson, D. Grimwade, H. Prentice, 1997, British journal of haematology.

Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia.

Robert K Hills, R. Hills, N. Russell, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

NPM1 mutation in AML: WHO and why?

D. Grimwade, 2006 .

Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance.

D. Grimwade, B. Huntly, A. Ivey, 2016, Blood.

Molecular Detection of Minimal Residual Disease Provides the Most Powerful Independent Prognostic Factor Irrespective of Clonal Architecture in Nucleophosmin (NPM1) Mutant Acute Myeloid Leukemia

P. Vyas, M. Simpson, R. Hills, 2014 .

Familial MDS with 5q — abnormality

G. Mufti, D. Grimwade, R. Dalton, 1993, British journal of haematology.

Detection of minimal residual disease (MRD) in APL by "real-time" RT-PCR: Analysis of cases entered into the UK MRC ATRA trial.

A. Wheatley, D. Grimwade, E. Solomon, 1999 .

Predictors of Clinical Response in Patients with High Risk Acute Myeloid Leukemia Receiving Treatment with the Histone Deacetylase Inhibitor Sodium Valproate.

C. Bradbury, C. Bunce, C. Craddock, 2005 .

Evaluation of Prospective Detection of PML-RARA and RARA-PML Fusion Transcripts by Real-Time Quantitative PCR (RQ-PCR) To Direct Pre-Emptive Therapy with Arsenic Trioxide (ATO) in Acute Promyelocytic Leukemia (APL) Patients Treated in the UK MRC AML15 Trial.

R. Hills, D. Grimwade, E. Solomon, 2007 .

Real-time quantitative PCR (RQ-PCR) detection of minimal residual disease (MRD) by optimized WT1 assay to enhance risk stratification in acute myeloid leukemia (AML): A European leukemia net study [Abstract]

R. Hills, S. Schnittger, C. Preudhomme, 2007 .

Rexinoid-triggered differentiation and tumor-selective apoptosis of AML by protein kinase A-mediated de-subordination of RXR

L. Altucci, H. Gronemeyer, A. Nebbioso, 2006 .

Defining The Translocation Mechanism In Therapy-Related Acute Promyelocytic Leukaemia

M. Segal, C. Felix, P. Fenaux, 2009 .

The clinical significance of cytogenetic abnormalities in acute myeloid leukaemia.

D. Grimwade, 2001, Best practice & research. Clinical haematology.

Real-time quantitative RT-PCR to detect fusion gene transcripts associated with AML.

D. Grimwade, R. Flora, 2004, Methods in molecular medicine.

Influence of genetic predisposition to thrombosis on natural history of acute promyelocytic leukaemia

S. Langabeer, D. Grimwade, A. Goldstone, 1997, British journal of haematology.

Getting to the heart of improving outcomes for patients with acute promyelocytic leukemia.

D. Grimwade, A. Burnett, 2012, Oncology.

Reply to S. Nagai et al

F. Lo‐Coco, R. Hills, D. Grimwade, 2010 .

Idarubicin and ATRA Is as Effective as MRC Chemotherapy in Patients with Acute Promyelocytic Leukaemia with Lower Toxicity and Resource Usage: Preliminary Results of the MRC AML15 Trial.

R. Hills, N. Russell, A. Hunter, 2007 .

The pathogenesis and management of the coagulopathy of acute promyelocytic leukaemia

D. Grimwade, B. Hunt, K. Breen, 2012, British journal of haematology.

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.

Simona Soverini, Giovanni Martinelli, Susan Branford, 2006, Blood.

Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for "prime time"?

D. Grimwade, S. Freeman, 2014, Hematology. American Society of Hematology. Education Program.

Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party.

Torsten Haferlach, Claude Preudhomme, Wolfgang Kern, 2018, Blood.

Genetically distinct leukemic stem cells in human CD34− acute myeloid leukemia are arrested at a hemopoietic precursor-like stage

P. Vyas, A. Mead, C. Craddock, 2016, The Journal of experimental medicine.

Assessment of Minimal Residual Disease in Standard-Risk AML.

Yashma Patel, Robert K Hills, Hassan Farah, 2016, The New England journal of medicine.

Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for "prime time"?

D. Grimwade, S. Freeman, David Grimwade, 2014, Blood.

Can we say farewell to monitoring minimal residual disease in acute promyelocytic leukaemia?

R. Hills, D. Grimwade, J. Jovanovic, 2014, Best practice & research. Clinical haematology.

Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study.

V. V. D. van der Velden, R. Hills, S. Schnittger, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Global down-regulation of HOX gene expression in PML-RARalpha + acute promyelocytic leukemia identified by small-array real-time PCR.

D. Grimwade, M. McMullin, F. Cotter, 2003, Blood.

Biology and management of relapsed acute myeloid leukaemia

C. Craddock, P. Moss, D. Grimwade, 2005, British journal of haematology.

The European LeukemiaNet: achievements and perspectives

P. Schrotz-King, H. Döhner, H. Einsele, 2011, Haematologica.

Guidelines on the management of acute myeloid leukaemia in adults

C. Craddock, D. Grimwade, G. Jackson, 2006, British journal of haematology.

Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials.

R. Hills, D. Grimwade, C. Harrison, 2010, Blood.

The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial.

D. Grimwade, C. Harrison, A. Goldstone, 2001, Blood.

Identification of a potential “hotspot” DNA region in the RUNX1 gene targeted by mitoxantrone in therapy‐related acute myeloid leukemia with t(16;21) translocation

F. Lo‐Coco, L. Chessa, D. Grimwade, 2009, Genes, chromosomes & cancer.

Allogeneic hematopoietic cell transplantation improves outcome of adults with t(6;9) acute myeloid leukemia: results from an international collaborative study

E. Estey, R. Schlenk, R. Hills, 2019, Haematologica.

Characterisation of the PML/RAR alpha rearrangement associated with t(15;17) acute promyelocytic leukaemia.

D. Grimwade, E. Solomon, 1997, Current topics in microbiology and immunology.

The metabolites of nitric oxide in sickle‐cell disease

D. Grimwade, D. Rees, J. Porter, 1995, British journal of haematology.

Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.

E. Estey, H. Döhner, T. Naoe, 2009, Blood.

Topoisomerase II and leukemia

N. Osheroff, C. Felix, D. Grimwade, 2014, Annals of the New York Academy of Sciences.

Mutation of the RAD51C gene in a Fanconi anemia–like disorder

Franca Fraternali, Nazneen Rahman, Christopher G Mathew, 2010, Nature Genetics.

The pathogenesis of acute promyelocytic leukaemia: evaluation of the role of molecular diagnosis and monitoring in the management of the disease

D. Grimwade, David Grimwade, 1999, British journal of haematology.

The epigenetic regulator PLZF represses L1 retrotransposition in germ and progenitor cells

T. Down, D. Grimwade, E. Solomon, 2013, The EMBO journal.

Downregulation of the Wnt inhibitor CXXC5 predicts a better prognosis in acute myeloid leukemia.

T. Haferlach, R. Hills, S. Schnittger, 2015, Blood.

Pathogenesis, Diagnosis and Monitoring of Residual Disease in Acute Promyelocytic Leukaemia

A. Reiter, D. Grimwade, E. Lengfelder, 2004, Acta Haematologica.

DNA topoisomerase II in therapy-related acute promyelocytic leukemia.

M. Segal, N. Osheroff, C. Felix, 2005, The New England journal of medicine.

Characterization of cryptic rearrangements and variant translocations in acute promyelocytic leukemia.

P. Freemont, D. Sheer, S. Langabeer, 1997, Blood.

Acute promyelocytic leukemia: a model for the role of molecular diagnosis and residual disease monitoring in directing treatment approach in acute myeloid leukemia

D. Grimwade, F. Coco, 2002, Leukemia.

Extramedullary disease in acute promyelocytic leukemia.

D. Grimwade, G. Evans, 1999, Leukemia & lymphoma.

Diagnostic and therapeutic management of eosinophilia-associated chronic myeloproliferative disorders

A. Reiter, N. Cross, D. Grimwade, 2007, Haematologica.

Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia.

M. Rondoni, G. Martinelli, C. Preudhomme, 2007, Blood.

Leukemia diagnosis: today and tomorrow

T. Haferlach, M. Béné, C. Haferlach, 2015, European journal of haematology.

PML nuclear bodies in the pathogenesis of acute promyelocytic leukemia: active players or innocent bystanders?

D. Grimwade, N. Brown, M. Ramalho, 2009, Frontiers in bioscience.

Deletion and reduced expression of the Fanconi anemia FANCA gene in sporadic acute myeloid leukemia

I. Vořechovský, S. Hodgson, S. Hodgson, 2004, Leukemia.

Independent Prognostic Factors for Aml Outcome Pre-treatment Prognostic Factors

R. Hills, D. Grimwade, R. K. Hills, 2022 .

Expression of T-lineage-affiliated transcripts and TCR rearrangements in acute promyelocytic leukemia: implications for the cellular target of t(15;17).

T. Haferlach, E. Macintyre, D. Grimwade, 2006, Blood.

Tumour lysis following hydrocortisone prior to a blood product transfusion in T-cell acute lymphoblastic leukaemia.

D. Grimwade, C. Tiley, R. Powles, 1992, Leukemia & lymphoma.

Genome-wide association study identi ﬁ es susceptibility loci for acute myeloid leukemia

Lara E Sucheston-Campbell, Lara E. Sucheston-Campbell, C. Gieger, 2022 .

Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia

I. Weissman, P. Vyas, C. Craddock, 2013, Leukemia.

Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome – a phase‐II study

S. Schnittger, C. Haferlach, A. Reiter, 2008, British journal of haematology.

Prognostic impact of KMT2E transcript levels on outcome of patients with acute promyelocytic leukaemia treated with all‐trans retinoic acid and anthracycline‐based chemotherapy: an International Consortium on Acute Promyelocytic Leukaemia study

A. Ganser, S. Schrier, F. Lo‐Coco, 2014, British journal of haematology.

Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide

E. Estey, R. Schlenk, R. Hills, 2017, Leukemia.

Acute promyelocytic leukemia: where does it stem from?

T. Enver, D. Grimwade, 2004, Leukemia.

Relationship between FLT 3 mutation status , biologic characteristics , and response to targeted therapy in acute promyelocytic leukemia

R. Hills, A. Pizzey, K. Mills, 2005 .

De fi ning minimal residual disease in acute myeloid leukemia : which platforms are ready for “ prime time ” ?

D. Grimwade, S. Freeman, 2014 .

Refinement of cytogenetic classification in acute myeloid leukaemia: Determination of prognostic significance of rarer recurring chromosomal abnormalities amongst 5,876 younger adult patients treated in the UK Medical Research Council trials

R. Hills, D. Grimwade, C. Harrison, 2010 .

Cytogenetics of childhood AML from UK medical research council treatment trials, AML10 & 12.

R. Hills, D. Grimwade, C. Harrison, 2003 .

Identification of the t(15;17) in AML FAB types other than M3: evaluation of the role of molecular screening for the PML/RARα rearrangement in newly diagnosed AML

B. Bain, P. Freemont, S. Langabeer, 1999 .

Identification of the t(15;17) in AML FAB types other than M3: evaluation of the role of molecular screening for the PML/RARalpha rearrangement in newly diagnosed AML. The Medical Research Council (MRC) Adult Leukaemia Working Party.

B. Bain, P. Freemont, P. Freemont, 1999, British journal of haematology.

Independent prognostic variables in acute myeloid leukaemia.

R. Hills, D. Grimwade, Matthew L. Smith, 2011, Blood reviews.

Detection and molecular monitoring of FIP1L1-PDGFRA-positive disease by analysis of patient-specific genomic DNA fusion junctions

A. Jones, A. Reiter, F. Grand, 2009, Leukemia.

Repression of CD2 gene expression is mediated by an AP-2 related factor.

D. Grimwade, T. Crompton, S. Outram, 2001, Biochemical and biophysical research communications.

Clinical impact of BAALC expression in high-risk acute promyelocytic leukemia.

A. Ganser, S. Schrier, F. Lo‐Coco, 2017, Blood advances.

The T-lineage-affiliated CD2 gene lies within an open chromatin environment in acute promyelocytic leukemia cells.

C. Craddock, A. Pizzey, D. Grimwade, 2002, Cancer research.

Cells Chromatin Environment in Acute Promyelocytic Leukemia Gene Lies within an Open CD 2 The T-Lineage-affiliated Updated

C. Craddock, A. Pizzey, D. Grimwade, 2002 .

Risk-adapted treatment of acute promyelocytic leukemia: results from the International Consortium for Childhood APL.

R. Foà, G. Leverger, F. Lo Coco, 2018, Blood.

Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study

A. Ganser, S. Schrier, F. Lo‐Coco, 2014, Annals of Hematology.

overexpression in acute promyelocytic leukemia Loss of imprinting at the 14 q 32 domain is associated with microRNA

J. Gribben, D. Grimwade, B. Young, 2014 .

Wilms’ Tumour 1 (WT1) peptide vaccination in patients with acute myeloid leukaemia induces short-lived WT1-specific immune responses

C. Craddock, A. Khwaja, D. Grimwade, 2013, British journal of haematology.

High ΔNp73/TAp73 ratio is associated with poor prognosis in acute promyelocytic leukemia.

A. Ganser, S. Schrier, F. Lo‐Coco, 2015, Blood.

Rexinoid-triggered differentiation and tumor-selective apoptosis of acute myeloid leukemia by protein kinase A-mediated desubordination of retinoid X receptor.

L. Altucci, H. Gronemeyer, A. Nebbioso, 2005, Cancer research.

The molecular pathogenesis of acute promyelocytic leukaemia: implications for the clinical management of the disease.

D. Grimwade, A. R. Mistry, E. Solomon, 2003, Blood reviews.

The significance of minimal residual disease in patients with t(15;17).

D. Grimwade, 2002, Best practice & research. Clinical haematology.

Atypical mRNA fusions in PML‐RARA positive, RARA‐PML negative acute promyelocytic leukemia

S. Schnittger, C. Haferlach, A. Reiter, 2010, Genes, chromosomes & cancer.

Characterization of acute promyelocytic leukemia cases lacking the classic t(15;17): results of the European Working Party. Groupe Français de Cytogénétique Hématologique, Groupe de Français d'Hematologie Cellulaire, UK Cancer Cytogenetics Group and BIOMED 1 European Community-Concerted Action "Mole

F. Birg, A. Hagemeijer, R. Berger, 2000, Blood.

EVI1 expression in acute myeloid leukaemia

B. Bain, S. Langabeer, D. Grimwade, 2001, British journal of haematology.

Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.

R. Hills, N. Russell, R. Clark, 2015, The Lancet. Oncology.

Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European LeukemiaNet

F. Lo‐Coco, W. Hofmann, S. Lehmann, 2015, Leukemia.

Acute promyelocytic leukemia: a paradigm for differentiation therapy.

D. Grimwade, A. R. Mistry, E. Solomon, 2010, Cancer treatment and research.

Assessment of Minimal Residual Disease in Standard-Risk AML.

R. Hills, D. Grimwade, A. Ivey, 2016, The New England journal of medicine.

The cryptic IRF2BP2-RARA fusion transforms hematopoietic stem/progenitor cells and induces retinoid-sensitive acute promyelocytic leukemia

D. Grimwade, N. Gutiérrez, A. López, 2017, Leukemia.

Myocardial infarction with intracardiac thrombosis as the presentation of acute promyelocytic leukemia: diagnosis and follow-up by cardiac magnetic resonance imaging.

T. Cahill, D. Grimwade, N. Herring, 2011, Circulation.

Should minimal residual disease monitoring be the standard of care for all patients with acute promyelocytic leukemia?

M. Tallman, D. Grimwade, 2011, Leukemia research.

Minimal residual disease detection in acute promyelocytic leukemia by reverse-transcriptase PCR: evaluation of PML-RAR alpha and RAR alpha-PML assessment in patients who ultimately relapse.

S. Langabeer, D. Grimwade, E. Solomon, 1996, Leukemia.

rearrangements leukemia distinguishes cases with underlyingPLZF/RARA gene A new morphologic classification system for acute promyelocytic

F. Birg, A. Hagemeijer, S. Fenu, 2013 .

A new morphologic classification system for acute promyelocytic leukemia distinguishes cases with underlying PLZF/RARA gene rearrangements.

F. Birg, A. Hagemeijer, S. Fenu, 2000, Blood.

leukemia distinguishes cases with underlying A new morphologic classification system for acute promyelocytic

Marina, F. Birg, A. Hagemeijer, 2000 .

Characteristics and outcome of patients with acute myeloid leukaemia and t(8;16)(p11;p13): results from an International Collaborative Study *

E. Estey, J. Esteve, R. Schlenk, 2021, British journal of haematology.

Hyperdiploidy with 49–65 chromosomes represents a heterogeneous cytogenetic subgroup of acute myeloid leukemia with differential outcome

R. Hills, D. Grimwade, C. Harrison, 2014, Leukemia.

Prolonged molecular remission in PML-RARα-positive acute promyelocytic leukemia treated with minimal chemotherapy followed by maintenance including the histone deacetylase inhibitor sodium valproate

D. Grimwade, M. McMullin, A. Thompson, 2005, Leukemia.

Diagnostic and prognostic value of cytogenetics in acute myeloid leukemia.

K. Mrózek, D. Grimwade, 2011, Hematology/oncology clinics of North America.

Impact of diagnostic cytogenetics on outcome in AML: Analysis of 1,613 patients entered into the UK MRC AML 10 trial.

R. Gray, D. Grimwade, C. Harrison, 1996 .

The Cks1/Cks2 axis fine-tunes Mll1 expression and is crucial for MLL-rearranged leukaemia cell viability

T. Haferlach, D. Grimwade, T. Milne, 2018, Biochimica et biophysica acta. Molecular cell research.

Normal Hematopoietic Progenitor Subsets Have Distinct Reactive Oxygen Species, BCL2 and Cell-Cycle Profiles That Are Decoupled from Maturation in Acute Myeloid Leukemia

P. Vyas, C. Bradbury, R. Hills, 2016, PloS one.

European LeukemiaNet recommendations from an international expert panel , on behalf of the Diagnosis and management of acute myeloid leukemia in adults :

C. Bloomfield, E. Estey, T. Naoe, 2009 .

Elevated FOSB‐expression; a potential marker of valproate sensitivity in AML

C. Bradbury, F. Khanim, R. Hayden, 2009, British journal of haematology.

Pml nuclear body disruption cooperates in APL pathogenesis and impairs DNA damage repair pathways in mice.

R. Hills, P. Salomoni, D. Grimwade, 2018, Blood.

An immunophenotypic pre‐treatment predictor for poor response to induction chemotherapy in older acute myeloid leukaemia patients: blood frequency of CD34+ CD38low blasts

P. Vyas, R. Hills, N. Russell, 2015, British journal of haematology.

Images in Cardiovascular Medicine Myocardial Infarction With Intracardiac Thrombosis as the Presentation of Acute Promyelocytic Leukemia Diagnosis and Follow-Up by Cardiac Magnetic Resonance Imaging

T. Cahill, D. Grimwade, N. Herring, 2011 .

Improving acute promyelocytic leukemia (APL) outcome in developing countries through networking, results of the International Consortium on APL.

A. Ganser, S. Schrier, F. Lo‐Coco, 2013, Blood.

Comprehensive genomic screens identify a role for PLZF-RARalpha as a positive regulator of cell proliferation via direct regulation of c-MYC.

J. Dick, J. Licht, Jared Flatow, 2009, Blood.

Risk-adapted treatment of acute promyelocytic leukemia : results from International Consortium for Childhood APL Running title : risk-adapted therapy for childhood APL

R. Foà, G. Leverger, D. Grimwade, 2018 .

Central nervous system involvement in relapsed acute promyelocytic leukemia

D. Grimwade, A. Pession, G. Kaspers, 2009, Pediatric blood & cancer.

The molecular anatomy of the FIP1L1-PDGFRA fusion gene

R. Yeh, M. Baccarani, G. Martinelli, 2009, Leukemia.

M. Dyer, N. Potter, N. Russell, 2021, Leukemia.

Impact of Cytogenetics on Clinical Outcome in AML

D. Grimwade, 2007 .

Prognostic significance of additional cytogenetic abnormalities and FLT3 mutations in acute promyelocytic leukemia

D. Grimwade, R. Dillon, 2014, Leukemia & lymphoma.

RARα-PLZF overcomes PLZF-mediated repression of CRABPI, contributing to retinoid resistance in t(11;17) acute promyelocytic leukemia

P. Pandolfi, K. Mills, R. Hobbs, 2007, Proceedings of the National Academy of Sciences.

Systematic Evaluation of DNA-Based Quantitative-Polymerase Chain Reaction (Q-PCR) Assays to Track Treatment Response in Patients with JAK2-V617F Associated Myeloproliferative Neoplasms: A Joint European LeukemiaNet/ MPN&MPNr-EuroNet Study

T. Barbui, P. Guglielmelli, A. Pancrazzi, 2011 .

Acute myeloid leukaemia with mutated NPM1 presenting with extensive bone marrow necrosis and Charcot–Leyden crystals

D. Grimwade, D. Culligan, A. Ivey, 2013, International Journal of Hematology.

Presenting features and treatment outcome of acute promyelocytic leukemia arising after multiple sclerosis

J. Esteve, F. Lo‐Coco, M. Sanz, 2011, Haematologica.

Minimal residual disease evaluation in acute myeloid leukaemia

D. Grimwade, John A Liu Yin, David Grimwade, 2002, The Lancet.

The relationship between FLT3 mutation status: biological characteristics and outcome in patients with acute promyelocytic leukaemia.

R. Hills, K. Mills, D. Grimwade, 2003 .

Pre-Transplant NPM1 Mutant Transcript Level Is Highly Predictive of Outcome after Allograft and Thresholds Are Dependent on FLT3 ITD Status

N. Potter, R. Hills, N. Russell, 2018, Blood.

European leukemianet-integration of the leading national leukemia networks (CML, AML, ALL, CLL, MDS, CMPD) another interdisciplinary partner groups in Europe

T. Haferlach, M. Baccarani, U. Mansmann, 2007 .

A functional variant in the core promoter of the CD95 cell death receptor gene predicts prognosis in acute promyelocytic leukemia.

R. Hills, J. Allan, D. Grimwade, 2012, Blood.

A functional variant in the core promoter of the CD 95 cell death receptor gene predicts prognosis in acute promyelocytic leukemia Running Title : CD 95 SNP rs 2234767 in APL

R. Hills, J. Allan, D. Grimwade, 2011 .

Author Correction: Genome-wide association study identifies susceptibility loci for acute myeloid leukemia

Lara E. Sucheston-Campbell, C. Gieger, A. Skol, 2022, Nature communications.

Gene-expression profiling in acute myeloid leukemia.

T. Haferlach, D. Grimwade, 2004, The New England journal of medicine.

PcG methylation of the HIST1 cluster defines an epigenetic marker of acute myeloid leukemia

S. Spicuglia, D. Grimwade, G. Bidaut, 2014, Leukemia.

Clinical relevance of failed and missing cytogenetic analysis in acute myeloid leukaemia

R. Hills, D. Grimwade, C. Harrison, 2017, Leukemia.

recommendations from an international expert panel, on behalf of the Diagnosis and management of acute myeloid leukemia in adults:

C. Bloomfield, E. Estey, T. Naoe, 2010 .

European LeukemiaNet recommendations from an international expert panel , on behalf of the Diagnosis and management of acute myeloid leukemia in adults :

C. Bloomfield, E. Estey, T. Naoe, 2010 .

Minimal residual disease-directed therapy in acute myeloid leukemia.

R. Schlenk, D. Grimwade, R. Walter, 2015, Blood.

Can we say farewell to monitoring minimal residual disease in acute promyelocytic leukaemia?

R. Hills, D. Grimwade, J. Jovanovic, 2014, Best practice & research. Clinical haematology.

R. Hills, D. Grimwade, C. Harrison, 2010, Blood.

Independent prognostic factors for AML outcome.

R. Hills, D. Grimwade, 2009, Hematology. American Society of Hematology. Education Program.

Expression of T-lineage-affiliated transcripts and TCR rearrangements in acute promyelocytic leukemia: implications for the cellular target of t(15;17).

T. Haferlach, E. Macintyre, D. Grimwade, 2006, Blood.

Characterisation of Genome-Wide PLZF/RARA Target Genes

F. Bertucci, S. Spicuglia, K. Mills, 2011, PloS one.

The Cks1/Cks2 axis ﬁ ne-tunes Mll1 expression and is crucial for MLL-rearranged leukaemia cell viability

D. Grimwade, E. Voisset, Torsten Haferlach, 2022 .

CORRESPONDENCE: Assessment of minimal residual disease in standard-risk AML: Assessment of minimal residual disease in standard-risk AML

R. Hills, D. Grimwade, Adam Ivey, 2016 .

Strikingly different molecular relapse kinetics in NPM 1 c , PML-RARA , RUNX 1-RUNX 1 T 1 , and CBFB-MYH 11 acute myeloid leukemias

S. Schnittger, D. Grimwade, Ingrid Beier Ommen, 2009 .

Divergent Dynamics of Epigenetic and Genetic Heterogeneity in Relapsed Acute Myeloid Leukemia

Francine E. Garrett-Bakelman, Anna L. Brown, C. Mason, 2015 .

Expression of T-lineage affiliated transcripts and TCR rearrangements in acute promyelocytic leukemia: implications for the cellular target of the t(15;17)

D. Grimwade, F. Davi, V. Asnafi, 2006 .